MDVN : Analysis & Opinions

  1. Pfizer Acquires Medivation for $14 Billion (PFE, MDVN)

    August 21, 2016
    Pfizer has agreed to pay $81.50 per share for Medivation, implying a premium value compared with the $52.50 offer made by ...
  2. Pfizer, Celgene Pursue Medivation (PFE, CELG)

    July 6, 2016
    Sanofi isn't the only one interested in Medivation. Pfizer and Celgene also signed confidentiality agreements.
  3. How Biotech Companies Expecting M&A Deals Can Offer High Returns ...

    May 17, 2016
    With a 35% decline, consolidation appears imminent in the biotech sector. Here are the potential M&A candidates and how to ...
  4. Breaking Down XBI: 3 Components That Are Most Attractive

    May 10, 2016
    Explore stocks from the SPDR S&P Biotech ETF, with consideration given to fundamentals and the status of drug candidates ...
  5. Three 2015 Losers on the Comeback Trail (TWTR, AMBA)

    March 2, 2016
    Twitter, Ambarella and Medivation show buying interest after getting pummeled in 2015.
  6. Triangle Stock Breakouts to Kick Off 2016 (GIS, SEM)

    January 4, 2016
    These stocks are near triangle chart pattern breakout points, presenting trading opportunities to kick off 2016.
  7. Scrutinizing Buy Signals in These Stocks

    May 13, 2015
    Four stocks to consider buying now based on their uptrends and recent pullbacks. Even a great looking stock isn't always ...
  8. 3 Biotech Stocks With Rising Short Interest

    April 28, 2015
    While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the March 31 and April ...
  9. It's No Accident That Drugs Are Expensive

    August 30, 2013
    Branded drugs are expensive in large part because it's expensive and risky to develop them
Trading Center